Baidu
map

EBioMedicine:分类和回归树分析确定儿童1型糖尿病的亚组

2022-08-18 从医路漫漫 MedSci原创

儿童和青春期糖尿病分为1型,由自身免疫介导的对产生胰岛素的胰岛b细胞的破坏引起;2型,是在胰岛素抵抗和肥胖的背景下胰岛素分泌不足引起的;以及特定类型的糖尿病和其他原因如单基因糖尿病综合征)

背景:糖尿病是儿童时期最常见的慢性病之一。根据最近的估计,全世界有超过110万儿童和青少年患有糖尿病。儿童和青春期糖尿病分为1型,这是最常见的形式,由自身免疫介导的对产生胰岛素的胰岛b细胞的破坏引起;2型,是在胰岛素抵抗和肥胖的背景下胰岛素分泌不足引起的;以及特定类型的糖尿病和其他原因(如单基因糖尿病综合征)。该分类是分配治疗方案的基础。然而,临床表现和严重程度有相当大的差异,这可能导致诊断时围绕糖尿病类型和适当治疗的不确定性。这导致了其他参数,如b细胞功能和胰岛素敏感性,可能有助于区分自身免疫和非自身免疫形式的糖尿病,使用1型糖尿病遗传风险评分和临床特征的组合可以预测单基因糖尿病。

一直没解决的问题是,在年轻发病的1型糖尿病中,是否存在亚型、内型或治疗型,就像成人2型糖尿病和儿童时期的过敏报道一样。最近提出了与年龄相关的1型糖尿病内型,其基础是T和B细胞对自身抗原的反应以及患者胰岛中的主要细胞类型。糖尿病患者的遗传负荷和功能b细胞储备也随年龄而变化。最后,免疫治疗的反应与年龄相关,进一步表明1型糖尿病内型可能具有明显的致病特征和治疗反应性。

目的:本研究的目的是使用监督多变量方法区分20岁前诊断为1型糖尿病患者的临床相关亚组。C肽作为残余B细胞功能的指标,被选为结果指标,因为它与中长期疾病严重程度和预后有关。并经常在新发1型糖尿病患者的临床试验中用作合格标准。我们使用分类和回归树(CART)分析方法来搜索与德国DiMelli队列研究中登记的1192名新发糖尿病患者的C肽浓度相关的算法。在第二个大型队列中评估了模型的有效性和预后相关性,并使用额外的生化测量来搜索已确定组中潜在的发病和/或治疗异质性。经验证的算法定义了具有预后和潜在治疗相关性的不同亚组。

方法:采用多变量分类回归树(CART)分析方法,对1192例20岁前新诊断的糖尿病患者进行C肽残留量不同的亚组分析。模型的稳健性在确认和预后队列中进行了评估(n=2722)。

结果分析选择年龄、糖化血红蛋白(HbA1c)和体重指数(BMI)作为分裂参数,将患者分为7个胰岛自身抗体阳性组和3个自身抗体阴性组。两组在遗传学、炎症标志物、糖尿病家族史、血脂、25-OH-维生素D3、胰岛素治疗、胰岛素敏感性和胰岛素自身免疫等方面存在显著差异,并对可能存在不同病因和预后的患者进行分层。在最年轻的胰岛自身抗体阳性组和C-肽值最低的患者中,干扰素-ɣ和/或肿瘤坏死因子炎症信号丰富,而在年龄较大的患者中发现更高的体重指数和2型糖尿病特征。中位随访7年时HbA1c的持续差异证明了预后的相关性。

图1多变量CART模型用于将患有新发糖尿病的DiMelli参与者分类为亚组。该模型分别应用于1088例胰岛自身抗体阳性患者(A)和104例胰岛自身抗体阴性患者(B),以空腹C肽浓度(C)作为结果标记物。性别、确诊时的年龄、确诊的天数、糖化血红蛋白、体重指数和抑郁自评量表、1型糖尿病的一级家族史和任何其他形式的糖尿病的一级家族史都是模型中可能的预测变量。在这些变量中,CART模型为自身抗体阳性患者选择了年龄、HbA1c和BMI,为自身抗体阴性患者选择了BMI和HbA1c。模型选择的每一种分离物的P值=0.001[CART]。红线显示中间带。病人的人数显示在括号中。BMI,体重指数;HbA1c,血红蛋白A1c;SDS,标准差分数。

表1:主要分析中包括的DiMelli队列中由CART定义的胰岛自身抗体阳性患者群体的特征。

图2.从主要分析中包括的DiMelli参与者派生的CART定义的子组的特征。雷达图显示了诊断时1088名胰岛自身抗体阳性患者(A)和104名胰岛自身抗体阴性患者(B)的CART组。如表1和表2所示,所示变量在两组之间非常显著。雷达图将组间观察到的差异转换为每个变量的全图范围。

表2:主要分析包括在DiMelli队列中的CART定义的胰岛自身抗体阴性患者组的特征。

图3.DiMelli的805例胰岛自身抗体阳性患者的糖尿病诊断中的炎症标记物(OLINK炎症小组)。(A)这些数据被用来生成热图并确定四组患者。热图显示了这些簇中信息量最大的蛋白质。右侧显示空腹C肽。(B)CART定义的患者组内四个组的频率分布。(C)按炎症聚集性分层的P1和P3组患者的空腹C肽浓度。

结论:这项多变量分析揭示了年轻糖尿病患者中具有潜在致病和治疗相关性的亚组。

原文出处:Achenbach P,  Hippich M,  Zapardiel-Gonzalo J,et al.A classification and regression tree analysis identifies subgroups of childhood type 1 diabetes.EBioMedicine 2022 Jul 05;82

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1997158, encodeId=77de199e158c5, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu Aug 25 13:07:25 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774085, encodeId=dff71e740851a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Nov 23 21:07:25 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919485, encodeId=27df191948543, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Nov 13 16:07:25 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859290, encodeId=9957185929002, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Nov 28 08:07:25 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577918, encodeId=85e915e7918be, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Aug 17 02:07:25 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611698, encodeId=e14c16116984c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 17 02:07:25 CST 2022, time=2022-08-17, status=1, ipAttribution=)]
    2022-08-25 linagood
  2. [GetPortalCommentsPageByObjectIdResponse(id=1997158, encodeId=77de199e158c5, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu Aug 25 13:07:25 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774085, encodeId=dff71e740851a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Nov 23 21:07:25 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919485, encodeId=27df191948543, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Nov 13 16:07:25 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859290, encodeId=9957185929002, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Nov 28 08:07:25 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577918, encodeId=85e915e7918be, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Aug 17 02:07:25 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611698, encodeId=e14c16116984c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 17 02:07:25 CST 2022, time=2022-08-17, status=1, ipAttribution=)]
    2022-11-23 kalseyzl
  3. [GetPortalCommentsPageByObjectIdResponse(id=1997158, encodeId=77de199e158c5, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu Aug 25 13:07:25 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774085, encodeId=dff71e740851a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Nov 23 21:07:25 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919485, encodeId=27df191948543, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Nov 13 16:07:25 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859290, encodeId=9957185929002, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Nov 28 08:07:25 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577918, encodeId=85e915e7918be, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Aug 17 02:07:25 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611698, encodeId=e14c16116984c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 17 02:07:25 CST 2022, time=2022-08-17, status=1, ipAttribution=)]
    2022-11-13 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1997158, encodeId=77de199e158c5, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu Aug 25 13:07:25 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774085, encodeId=dff71e740851a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Nov 23 21:07:25 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919485, encodeId=27df191948543, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Nov 13 16:07:25 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859290, encodeId=9957185929002, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Nov 28 08:07:25 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577918, encodeId=85e915e7918be, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Aug 17 02:07:25 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611698, encodeId=e14c16116984c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 17 02:07:25 CST 2022, time=2022-08-17, status=1, ipAttribution=)]
    2022-11-28 jeanqiuqiu
  5. [GetPortalCommentsPageByObjectIdResponse(id=1997158, encodeId=77de199e158c5, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu Aug 25 13:07:25 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774085, encodeId=dff71e740851a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Nov 23 21:07:25 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919485, encodeId=27df191948543, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Nov 13 16:07:25 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859290, encodeId=9957185929002, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Nov 28 08:07:25 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577918, encodeId=85e915e7918be, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Aug 17 02:07:25 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611698, encodeId=e14c16116984c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 17 02:07:25 CST 2022, time=2022-08-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1997158, encodeId=77de199e158c5, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu Aug 25 13:07:25 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774085, encodeId=dff71e740851a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Nov 23 21:07:25 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919485, encodeId=27df191948543, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Nov 13 16:07:25 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859290, encodeId=9957185929002, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Nov 28 08:07:25 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577918, encodeId=85e915e7918be, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Aug 17 02:07:25 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611698, encodeId=e14c16116984c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 17 02:07:25 CST 2022, time=2022-08-17, status=1, ipAttribution=)]

相关资讯

Cardiovasc Diabetol :循环代谢物和分子脂质种类与1型糖尿病未来心血管发病率和死亡率相关

心血管疾病死亡率过高和寿命缩短主要是由于与普通人群相比,1型糖尿病患者动脉粥样硬化的发病更早,进展更迅速。

Adv Ther:肥胖和长期1型糖尿病患者周围神经病变的患病率和特征比较

胰岛素抵抗的特征性表现,包括代谢灵活性降低和脂肪和碳水化合物代谢转换能力受损,是连接肥胖和周围神经病变的假定因素。胰岛素抵抗与导致内皮功能障碍和微血管并发症的低度炎症有关。

SCRT:间充质干细胞移植治疗新诊断的1型糖尿病患者

糖尿病会导致严重的慢性并发症,对患者造成不可逆的多器官损害。这些并发症包括糖尿病肾病、神经病变、视网膜病变和心血管疾病。

PNAS:特殊的肠道菌群肽类或参与人类1型糖尿病的发生

来自波士顿学院等机构的科学家们通过研究识别出了一种特定类别的人类肠道细菌,其或能制造一种含有特殊氨基酸序列的蛋白,从而就能模拟1型糖尿病中被宿主机体免疫系统所靶向作用的胰岛素肽类。

Diabetologia:1型糖尿病和非1型糖尿病患者反调节激素的血糖阈值和对低血糖的症状反应

高胰岛素钳夹被广泛用于研究不同程度的低血糖对逆调节反应的影响,并被用来确定单个成分的激活阈值。

JAMA子刊:这类糖尿病患者癌症风险可升高5倍!都是胰岛素治疗惹的祸?

JAMA Oncol:1型糖尿病患者每日胰岛素剂量与癌症风险

Baidu
map
Baidu
map
Baidu
map